Search Results
Results found for "Domain Therapeutics"
- How Schild Analysis Protects Your Conclusions in GPCR Research
This Week in Premium: Sneak Peek Industry insights: Domain CMO; Pfizer–Metsera; Novo Nordisk strategy
- 📰 GPCR Weekly News, August 7 to 13, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans Towards the convergent therapeutic Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program Structure Therapeutics
- 📰 GPCR Weekly News, January 29 to February 4, 2024
Xavier Leroy for his new role as CEO of GIO Therapeutics Dr. Molecular mechanism of GPCR spatial organization at the plasma membrane Industry News Launch of GIO Therapeutics , founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation AVROBIO and Tectonic Therapeutic Announce Merger Trevena Inc Elevates Barry
- Inverse Agonists, Lymphatic Fixes & β-arrestin Tricks
Collaboration is the catalyst—let’s redefine what’s possible in GPCR-driven therapeutics.
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
Here’s what Premium Members accessed this week across four critical domains: Industry insights: Neurocrine
- GPR108 is required for gambogic acid inhibiting NF-κB signaling in cancer
Herein, we identified GPR108, a GPCR protein described in innate immune system, is a potential therapeutic Overall, our findings supported GPR108 as a promising therapeutic target of cancer, and provided a small
- Allosteric modulation of GPCRs: From structural insights to in silico drug discovery
orthosteric site), allosteric modulators offer new avenues for the regulation of GPCR function with potential therapeutic today, will facilitate structure-based discovery and development of allosteric modulators as novel therapeutic
- Ben Clements on Rescuing Opioids with GPCR Modulators
His work highlights how foundational GPCR science can drive therapeutic innovation.
- Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System
tools used to manipulate GPCR activity in an orthosteric site-independent manner to compounds with therapeutic development for each receptor, as well as the structural, signaling, pathophysiologic consequences, and therapeutic
- 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder, Maxion Therapeutics ) – BioLeader Interview Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK
- RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany...
So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic
- Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the β2 Adrenergic Receptor
unique allosteric signal transmission mechanisms between the Nb80-binding site and the extracellular domains
- 📰 GPCR Weekly News, May 27 to June 2, 2024
tunes mGlu5 receptor function, impacting synaptic transmission Orphan receptor GPR88 as a potential therapeutic the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies Industry News Structure Therapeutics
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
Antibodies, Bias, and the Expanding Modality Landscape Antibody therapeutics are now entering spaces once dominated by small molecules.
- 📰 GPCR Weekly News, September 25 to October 1, 2023
of traditional Chinese medicine in the treatment of glioblastoma multiforme Industry News Structure Therapeutics Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting
- 📰 GPCR Weekly News, September 18 to 24, 2023
GPCR Symposium about 'GPCRs as Therapeutic Modalities' rocked it! recommended by NICE for acute migraines Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Confo Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
Carlsson’s takeaway: AlphaFold is a powerful starting point, but domain expertise and experimental grounding
- 📰 Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)
activity, and structural evaluation Flavonoids as G Protein-coupled Receptors Ligands: New Potential Therapeutic back GPCR agonist after GSK changes course All-rounder among receptors inspires drug research Tectonic Therapeutic Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Carmot Therapeutics
- Orion and Peptilogics are pursuing AI-driven drug discovery to explore new functional chemical ...
are pursuing AI-driven drug discovery to explore new functional chemical space and precision-engineer therapeutics
- Building Backwards: Why Top-Down Models Could Revolutionize Pain Research
how inflammation, cognition, and pain circuits overlap , and how GPCRs might serve as more responsive therapeutic
- Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR
leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key therapeutic biology platform to identify potential GPCR targets and advance the development of new gastrointestinal therapeutics
- Discovery On Target, October 17-20, 2022, Boston, USA
and technologies, as well as target validation strategies for the discovery and development of novel therapeutic
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
activity without directly competing with ligands, potentially reducing side effects and increasing therapeutic the findings of this study have significant implications for drug design, personalised medicine, and therapeutic
- First AMA of 2026: GPCR Pharmacology, Biased Signaling & Mechanistic Clarity
The paper explores: Detection and quantification of signaling bias Influence of biased signaling on therapeutic
- Quantifying Receptor Selectivity in Modern Drug Discovery
Another produces a larger shift in EC₅₀ in one system than another, and we assume we’ve found therapeutic In the end, what matters therapeutically is the integrated response.
- ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships
FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics
- Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells...
As therapeutic options are limited, novel targets and agents for therapeutic intervention are urgently
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
cardiometabolic disease, and gain insights into novel approaches in neurodegeneration and antibody therapeutics missed by traditional screening methods, gaining a first-mover advantage in developing more effective therapeutics
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
his interview, Regulators of G protein Signaling (RGS proteins) might hold some of the most untapped therapeutic
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics














